Vijay V Upreti (Vijay Upreti)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 26

Top Venues

Clinical pharmacology and therapeutics

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology : advances and applications

Clinical and translational science

Amgen Inc San Francisco

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Amgen Inc San Francisco

United States

DIRECTOR, Head Clinical Pharmacology Hem/Onc Therapeutic Area. :: Clinical Pharmacology, Modeling & Simulation

Publications

Arya Pourzanjani, Saurabh Modi, Jamie N Connarn, Xinwen Zhang, Vijay V Upreti, Chih-Wei Lin, Khamir Mehta
A novel Bayesian generative approach for estimating tumor dynamics from published studies. CPT: pharmacometrics & systems pharmacology (2024)
Annie Lumen, Xinwen Zhang, Sandeep Dutta, Vijay V Upreti
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model. Clinical pharmacology and therapeutics 115 (5) (2024)
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, Yazdi K Pithavala, Srinivasu Poondru, Chirag Patel, Pavan Vaddady, Wendy Ankrom, Saroja Ramanujan, Nageshwar Budha, Michael Wu, Nahor Haddish-Berhane, Holger Fritsch, Azher Hussain, Jitendra Kanodia, Meng Li, Mengyao Li, Murad Melhem, Apurvasena Parikh, Vijay V Upreti, Neeraj Gupta
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical pharmacology and therapeutics 116 (3) (2024)
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, Nageshwar Budha, Ferdous Gheyas, Chi-Chung Li, Yuan Chen, Anne-Gaëlle Dosne, Niels Rode Kristensen, Mindy Magee, Mahesh N Samtani, Vikram Sinha, Kunal S Taskar, Vijay V Upreti, Jianning Yang, Jack Cook
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program. Clinical pharmacology and therapeutics 116 (2) (2024)
Annie Lumen, Xinwen Zhang, Sandeep Dutta, Vijay V Upreti
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model. Clinical pharmacology and therapeutics (2024)
Di Zhou, Roman Kischel, Sabine Stienen, Danielle Townsley, Alexander Sternjak, Michael Lutteropp, Julie Bailis, Matthias Friedrich, Benno Rattel, Khamir Mehta, Vijay V Upreti
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager. Clinical pharmacology and therapeutics (2024)
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, Nageshwar Budha, Ferdous Gheyas, Chi-Chung Li, Yuan Chen, Anne-Gaëlle Dosne, Niels Rode Kristensen, Mindy Magee, Mahesh N Samtani, Vikram Sinha, Kunal S Taskar, Vijay V Upreti, Jianning Yang, Jack Cook
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program. Clinical pharmacology and therapeutics (2024)
Arya Pourzanjani, Saurabh Modi, Jamie N Connarn, Xinwen Zhang, Vijay V Upreti, Chih-Wei Lin, Khamir Mehta
A novel Bayesian generative approach for estimating tumor dynamics from published studies. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Arya Pourzanjani, Saurabh Modi, Jamie N Connarn, Xinwen Zhang, Vijay V Upreti, Chih-Wei Lin, Khamir Mehta
A novel Bayesian generative approach for estimating tumor dynamics from published studies. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Annie Lumen, Xinwen Zhang, Sandeep Dutta, Vijay V Upreti
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model. Clinical pharmacology and therapeutics 115 (5) (2024)
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, Yazdi K Pithavala, Srinivasu Poondru, Chirag Patel, Pavan Vaddady, Wendy Ankrom, Saroja Ramanujan, Nageshwar Budha, Michael Wu, Nahor Haddish-Berhane, Holger Fritsch, Azher Hussain, Jitendra Kanodia, Meng Li, Mengyao Li, Murad Melhem, Apurvasena Parikh, Vijay V Upreti, Neeraj Gupta
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical pharmacology and therapeutics (2024)
Arya Pourzanjani, Saurabh Modi, Jamie N Connarn, Xinwen Zhang, Vijay V Upreti, Chih-Wei Lin, Khamir Mehta
A novel Bayesian generative approach for estimating tumor dynamics from published studies. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Malidi Ahamadi, Johannes Kast, Po-Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V Upreti
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. CPT: pharmacometrics & systems pharmacology 12 (2) (2023)
Malidi Ahamadi, Johannes Kast, Po-Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V Upreti
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. CPT: pharmacometrics & systems pharmacology 12 (2) (2023)
Xinwen Zhang, Annie Lumen, Hansen Wong, Jamie Connarn, Sandeep Dutta, Vijay V Upreti
A Mechanistic-Physiologically Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers. Clinical pharmacology and therapeutics (2023)
Marc R Yago, Khamir Mehta, Maitreyee Bose, Sharvari Bhagwat, Vivek S Chopra, Sandeep Dutta, Vijay V Upreti
Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome. Clinical pharmacokinetics (2023)
Hardik Mody, Ken Ogasawara, Xu Zhu, Dale Miles, Prathap Nagaraja Shastri, Jochem Gokemeijer, Michael Z Liao, Sreeneeranj Kasichayanula, Tong-Yuan Yang, Nagendra Chemuturi, Swati Gupta, Vibha Jawa, Vijay V Upreti
Best Practices & Considerations for Clinical Pharmacology & Pharmacometric Aspects for Optimal Development of CAR-T & TCR-T Cell Therapies: An Industry Perspective. Clinical pharmacology and therapeutics (2023)
Malidi Ahamadi, Johannes Kast, Po-Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V Upreti
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. CPT: pharmacometrics & systems pharmacology 12 (2) (2023)
Di Zhou, Lauren A Byers, Beate Sable, Marie-Anne Damiette Smit, Nooshin Hashemi Sadraei, Sandeep Dutta, Vijay V Upreti
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-like ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC). Journal of clinical pharmacology (2023)
Johannes Kast, Saeideh Nozohouri, Di Zhou, Marc R Yago, Po-Wei Chen, Malidi Ahamadi, Sandeep Dutta, Vijay V Upreti
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development. Clinical and translational science 15 (9) (2022)
Malidi Ahamadi, Johannes Kast, Po-Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V Upreti
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. CPT: pharmacometrics & systems pharmacology (2022)
Malidi Ahamadi, Johannes Kast, Po-Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V Upreti
Oncolytic Viral Kinetics Mechanistic Modeling of Talimogene Laherparepvec (IMLYGIC®) a First-in-Class Oncolytic Viral Therapy in patients with Advanced Melanoma. CPT: pharmacometrics & systems pharmacology (2022)
Michael Z Liao, Hans Prenen, Sandeep Dutta, Vijay V Upreti
The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. Cancer chemotherapy and pharmacology 88 (4) (2021)
Johannes Kast, Sandeep Dutta, Vijay V Upreti
Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors. Advances in therapy 38 (7) (2021)
Michael Z Liao, Johannes Kast, Marloes Berkhout, Hans Prenen, Sandeep Dutta, Vijay V Upreti
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]. Clinical pharmacology : advances and applications 12 (2020)
Michael Z Liao, Marloes Berkhout, Hans Prenen, Sandeep Dutta, Vijay V Upreti
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not. Clinical pharmacology : advances and applications 12 (2020)

Vijay V Upreti.css-eqlu8i{font-size:small;padding-left:4px;} (Vijay Upreti)

Publication Activity (10 Years)

Top Topics

Top Venues

Vijay V Upreti (Vijay Upreti)